138 294

Cited 0 times in

유방암 환자에서 종양 표지자로서 혈액내 TGF-β1의 분포에 관한 연구

DC Field Value Language
dc.contributor.author라선영-
dc.contributor.author정현철-
dc.date.accessioned2020-07-02T17:33:16Z-
dc.date.available2020-07-02T17:33:16Z-
dc.date.issued1998-
dc.identifier.issn0496-6872-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/176888-
dc.description.abstractPURPOSE: Transforming Growth Factor-beta1(TGF-beta1) is the most potent inhibitor of the progression of normal mammary epithelial cells through the cell cycle. However, advanced breast cancers are mostly refractory to TGF-beta mediated growth inhibition and produce large amounts of TGF-beta, which may enhance tumor cell invasion and metastasis by its effects on extracellular matrix. Yet, little is known about the association of TGF-beta1 with progression of malignant disease in vivo. In this study, we evaluated the preoperative and postoperative plama level of TGF- in breast cancer and analyzed the utility of plasma TGF-beta1 as possible tumor marker. MATERIALS AND METHODS: ELISA(enzyme-linked immunosorbent assay) was used to measure plasma TGF-beta1 level in 45 newly diagnosed breast cancer patients and in 15 normal healthy people, and the results were compared with clinicopathologic characteristics. RESULTS: The mean plasma TGF-beta1 levels were 1.73+/-0.47 ng/ml in normal people and 5.05+/-1.41 ng/ml in breast cancer patiens. In 37 operated patients, the preoperative plasma TGF-beta1 level was 6.34+/-1.34 ng/ml and decreased to 4.48+/-1.07 ng/ml in patients with follow-up after surgery and 4.74+/-0.79 ng/ml in patients with chemotherapy. However, there was no significant correlation between plasma TGF-beta1 level and known prognostic factors including tumor size, LN involvement, tumor grade, hormone receptor status, and pathology. CONCLUSION: These findings suggest that the plasma TGF-g level can be a tumor marker in breast cancer patients and the association with progression of breast cancer will be explored in future studies.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한암학회-
dc.relation.isPartOfJournal of the Korean Cancer Association (대한암학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title유방암 환자에서 종양 표지자로서 혈액내 TGF-β1의 분포에 관한 연구-
dc.title.alternativePlasma TGF-beta1 as a Tumor Marker in Breast Cancer Patients-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthor이화영-
dc.contributor.googleauthor라선영-
dc.contributor.googleauthor공수정-
dc.contributor.googleauthor안중배-
dc.contributor.googleauthor심광용-
dc.contributor.googleauthor박준오-
dc.contributor.googleauthor권현자-
dc.contributor.googleauthor유내춘-
dc.contributor.googleauthor정숙정-
dc.contributor.googleauthor정현철-
dc.contributor.googleauthor김주항-
dc.contributor.googleauthor이경식-
dc.contributor.googleauthor민진식-
dc.contributor.googleauthor김병수-
dc.contributor.googleauthor노재경-
dc.contributor.localIdA01316-
dc.contributor.localIdA03773-
dc.relation.journalcodeJ01813-
dc.subject.keywordTGF-beta-
dc.subject.keywordBreast cancer-
dc.subject.keywordCarcinogenesis-
dc.subject.keywordTumor marker-
dc.subject.keywordPrognostic factor-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor정현철-
dc.citation.volume30-
dc.citation.number5-
dc.citation.startPage935-
dc.citation.endPage942-
dc.identifier.bibliographicCitationJournal of the Korean Cancer Association (대한암학회지), Vol.30(5) : 935-942, 1998-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.